Diabetes

Dipeptidyl Peptidase-IV inhibitor phase II study initiated

Published in Cancer Weekly, February 15th, 2005

OSI Pharmaceuticals, Inc., (NASDAQ: OSIP) announced that Prosidion Limited, its U.K. subsidiary focused on the discovery and development of diabetes and obesity therapeutics, has initiated a phase II proof-of-concept and dose range finding study with the Dipeptidyl Peptidase-IV (DP-IV) inhibitor PSN9301.

The study will enroll approximately 60 patients into a 2-week in-house dosing and monitoring protocol. The study is being conducted in Berlin, Germany.

The development of inhibitors of DP-IV (an enzyme catalyzing the breakdown of the natural hormone Glucagon-like peptide-1 (GLP-1)) has become a very competitive area in the type 2 diabetes field....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-02-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry